SCHEMBL3205341

SCHEMBL3205341

Cn1c(=O)[nH]c2c(Cl)ccc(C(N)=O)c21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
ATM Q13315 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
MAP2K2 P36507 1/20 0.36
MAP2K1 Q02750 1/20 0.36
DPP4 P27487 1/20 0.36
LIN28A Q9H9Z2 1/20 0.34
BTK Q06187 1/20 0.33
JAK2 O60674 1/20 0.33
ADRA2A P08913 1/20 0.33
CLCN2 P51788 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2084672 0.82 NR4A2 (0.43) KMT2ARXFP1MAPTLMNAALDH1A1
SCHEMBL3210973 0.82 RXFP1 (0.36) KMT2ARXFP1MAPTLMNAHTT
SCHEMBL6766709 0.72 PARP1 (0.45) LMNADPP4
SCHEMBL3216452 0.71 MEN1 (0.40) KMT2ARXFP1LMNAALDH1A1HPGD
SCHEMBL2084414 0.69 CRHR1 (0.40) KMT2ARXFP1ALDH1A1HTTCSNK2A2
SCHEMBL15803863 0.65 KMT2A (0.39) KMT2AATMMAPTLMNAALDH1A1
SCHEMBL29859972 0.64 RXFP1 (0.56) KMT2ARXFP1LMNAALDH1A1MAOB
SCHEMBL13194528 0.64 RXFP1 (0.56) KMT2ARXFP1LMNAALDH1A1MAOB
SCHEMBL10407714 0.62 KMT2A (0.52) KMT2AATMRXFP1MAPTLMNA
SCHEMBL3121452 0.61 KMT2A (0.55) KMT2AATMMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056515-A1 BENZIMIDAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-04 US disclosed
EP-2088861-A2 BENZIMIDAZOLE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-08-19 EP disclosed
WO-2008051533-A2 BENZIMIDAZOLE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056515-A1 BENZIMIDAZOLE COMPOUNDS HRH4, SSTR5, CNR1 KMT2A 2341/4885ATM 3941/4885RXFP1 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.